The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Investing.com - 在制药巨头诺和诺德公司 (Novo Nordisk) (NYSE: NVO )宣布将终止与该远程医疗公司关于减肥药销售的合作后，Hims & Hers Health (NYSE: HIMS )股价暴跌20%。

诺和诺德公司周二宣布将停止与Hims & Hers的合作，终止通过NovoCare直接获取Wegovy的渠道。这家丹麦制药公司将拆股的主要原因归结为监管不合规和品牌保护问题，特别指出了Hims & Hers的营销做法以及继续销售复合Wegovy的个性化剂量。

Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

2025年6月24日， Hims & Hers Health（HIMS）披露1笔公司内部人交易情况。高管Okupe Oluyemi于2025年6月23日卖出2.31万股。 Hims & Hers Health, ...